UBC2 CRISPR Activation Plasmid (h): sc-404360-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- UBC2 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- UBC2 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by UBC2 CRISPR Activation Plasmid (h) and UBC2 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the UBE2A transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
UBC2 CRISPR Activation Plasmid (h) | sc-404360-ACT | 20 µg | $397.00 |
Human UBE2A encodes the E2 ubiquitin-conjugating enzyme UBC2, a core component of the ubiquitin–proteasome system that transfers activated ubiquitin from E1 enzymes to E3 ligases to support substrate ubiquitination. Through this activity, UBC2 helps regulate protein quality control, cell-cycle progression, and DNA damage responses by shaping ubiquitin signaling and proteostasis networks. UBE2A/UBC2 function is linked to pathways governing turnover of regulatory proteins and stress adaptation, making it relevant to studies of neuronal development, genome maintenance, and cellular homeostasis. Altered ubiquitination dynamics involving UBE2A have been associated with neurodevelopmental phenotypes and dysregulated proteostasis in disease-relevant contexts.
UBC2 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous UBE2A expression without altering the underlying DNA sequence.
UBC2 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the UBE2A locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the UBE2A transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous UBC2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native UBE2A locus and enabling the study of UBC2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of UBC2 pathway restoration in tumor cells with silenced or reduced UBE2A expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.